MedTrace Logo

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

NCT02906683 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 337

Last updated 2024-09-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.

Conditions

  • Stress Urinary Incontinence

Interventions

DRUG

TAS-303

Oral administration for 8 weeks, once daily.

DRUG

Placebo

Oral administration for 8 weeks, once daily.

Sponsors & Collaborators

  • Taiho Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Taiho Pharmaceutical Co., Ltd · Taiho Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-20
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02906683 on ClinicalTrials.gov